(Q37763121)

22 August 2017

title

Critical appraisal of pharmacoeconomic studies comparing TNF-alpha antagonists for rheumatoid arthritis treatment (English)

1 reference

22 August 2017

0 references

1 reference

0 references

Marco Barbieri

1

1 reference

22 August 2017

Michael F Drummond

2

1 reference

22 August 2017

Jaume Puig Junoy

3

1 reference

22 August 2017

Miguel Angel Casado Gómez

4

1 reference

22 August 2017

F Javier Ballina García

5

1 reference

22 August 2017

Pilar Blasco Segura

6

1 reference

22 August 2017

José Luis Poveda Andrés

7

1 reference

22 August 2017

publication date

1 December 2007

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

613-626

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Bayesian methods for evidence synthesis in cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

The death of cost-minimization analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.6.613

21 January 2018

Identifiers

DOI

10.1586/14737167.7.6.613

1 reference

22 August 2017

1 reference